JP2021528423A5 - - Google Patents

Info

Publication number
JP2021528423A5
JP2021528423A5 JP2020570938A JP2020570938A JP2021528423A5 JP 2021528423 A5 JP2021528423 A5 JP 2021528423A5 JP 2020570938 A JP2020570938 A JP 2020570938A JP 2020570938 A JP2020570938 A JP 2020570938A JP 2021528423 A5 JP2021528423 A5 JP 2021528423A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antigen
bispecific antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570938A
Other languages
English (en)
Japanese (ja)
Other versions
JP7403480B2 (ja
JP2021528423A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038163 external-priority patent/WO2019246356A1/en
Publication of JP2021528423A publication Critical patent/JP2021528423A/ja
Publication of JP2021528423A5 publication Critical patent/JP2021528423A5/ja
Application granted granted Critical
Publication of JP7403480B2 publication Critical patent/JP7403480B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570938A 2018-06-21 2019-06-20 二重特異性抗cd3×muc16抗体および抗pd-1抗体で癌を治療する方法 Active JP7403480B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688251P 2018-06-21 2018-06-21
US62/688,251 2018-06-21
PCT/US2019/038163 WO2019246356A1 (en) 2018-06-21 2019-06-20 Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies

Publications (3)

Publication Number Publication Date
JP2021528423A JP2021528423A (ja) 2021-10-21
JP2021528423A5 true JP2021528423A5 (cg-RX-API-DMAC7.html) 2022-06-23
JP7403480B2 JP7403480B2 (ja) 2023-12-22

Family

ID=67254001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570938A Active JP7403480B2 (ja) 2018-06-21 2019-06-20 二重特異性抗cd3×muc16抗体および抗pd-1抗体で癌を治療する方法

Country Status (26)

Country Link
US (1) US11254752B2 (cg-RX-API-DMAC7.html)
EP (2) EP4424712A3 (cg-RX-API-DMAC7.html)
JP (1) JP7403480B2 (cg-RX-API-DMAC7.html)
KR (1) KR102870971B1 (cg-RX-API-DMAC7.html)
CN (1) CN112312970B (cg-RX-API-DMAC7.html)
AU (1) AU2019290170B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020025476A2 (cg-RX-API-DMAC7.html)
CA (1) CA3103887A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003256A1 (cg-RX-API-DMAC7.html)
DK (1) DK3810281T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190088A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984972T3 (cg-RX-API-DMAC7.html)
FI (1) FI3810281T3 (cg-RX-API-DMAC7.html)
HU (1) HUE067985T2 (cg-RX-API-DMAC7.html)
IL (1) IL279251B2 (cg-RX-API-DMAC7.html)
MA (2) MA52962B1 (cg-RX-API-DMAC7.html)
MX (2) MX2020013905A (cg-RX-API-DMAC7.html)
MY (1) MY202134A (cg-RX-API-DMAC7.html)
PH (1) PH12020552115A1 (cg-RX-API-DMAC7.html)
PL (1) PL3810281T3 (cg-RX-API-DMAC7.html)
PT (1) PT3810281T (cg-RX-API-DMAC7.html)
RS (1) RS65886B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012137UA (cg-RX-API-DMAC7.html)
TW (2) TW202504917A (cg-RX-API-DMAC7.html)
WO (1) WO2019246356A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202007599B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682941B (zh) * 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
JP2023539525A (ja) * 2020-09-02 2023-09-14 ジェンマブ エー/エス 抗体療法
NL2027601B1 (en) * 2021-02-19 2022-09-19 Crm Therapeutics B V Target mediated endocytotic drug delivery
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
CN117015394A (zh) * 2021-03-12 2023-11-07 博际生物医药科技(杭州)有限公司 结合人TGFβ和PD-L1的双功能分子及其应用
EP4308160A4 (en) * 2021-03-18 2025-07-02 Memorial Sloan Kettering Cancer Center METHODS OF TREATING GYNECOLOGICAL CANCER USING COMBINATION THERAPY WITH MULTISPECIFIC ANTI-MUC16 X CD3 ANTIBODIES AND VEGF INHIBITORS
CN117320700A (zh) * 2021-04-02 2023-12-29 瑞泽恩制药公司 含有抗muc16 x抗cd3双特异性抗体的稳定制剂
JPWO2023033022A1 (cg-RX-API-DMAC7.html) 2021-08-31 2023-03-09
MX2024006187A (es) * 2021-11-24 2024-08-14 Regeneron Pharma Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4.
MX2024008055A (es) * 2022-01-07 2024-09-06 Regeneron Pharma Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.
US20250092135A1 (en) * 2022-01-10 2025-03-20 Nanjing Leads Biolabs Co., Ltd. Antibody and use thereof
WO2023176881A1 (ja) * 2022-03-16 2023-09-21 第一三共株式会社 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
MX2019004327A (es) * 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof

Similar Documents

Publication Publication Date Title
JP2022050618A5 (cg-RX-API-DMAC7.html)
IL313952A (en) Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment
FI3810281T3 (fi) Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
JP2019515008A5 (cg-RX-API-DMAC7.html)
JP2022078265A5 (cg-RX-API-DMAC7.html)
IL321717A (en) Anti-PD-1 antibodies for the treatment of lung cancer
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2019519499A5 (cg-RX-API-DMAC7.html)
JP2022532490A5 (cg-RX-API-DMAC7.html)
CN108602889A (zh) 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
JP2023505218A5 (cg-RX-API-DMAC7.html)
JP2015500822A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
TW202320827A (zh) 用於治療癌症之檢查點抑制劑和溶瘤病毒的組合
JP2023519807A5 (cg-RX-API-DMAC7.html)
JP2025134086A (ja) 関節リウマチを有する対象における疼痛を治療するための組成物および方法
JP2025509567A5 (cg-RX-API-DMAC7.html)
JP2025502061A5 (cg-RX-API-DMAC7.html)
JP2021518348A5 (cg-RX-API-DMAC7.html)
TW202034925A (zh) Cdk4/6抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
CN117693350A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
JP2024542879A5 (cg-RX-API-DMAC7.html)
IL314851A (en) Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
NZ781933B2 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer